Difference between revisions of "Team:Manchester-Graz/Design"

(Prototype team page)
 
Line 1: Line 1:
−
{{Manchester-Graz}}
+
{{Team:Manchester-Graz/CSS2}}
 +
{{Team:Manchester-Graz/Header2}}
 +
 
 
<html>
 
<html>
 +
<head>
 +
  <title>iGEM Manchester-Graz - Design</title>
 +
  <link href="design2.css" type="text/css" rel="stylesheet">
 +
</head>
 +
 +
<body>
 +
 +
<div id="fixednavi">
 +
<a class="navi" href="https://2015.igem.org/Team:Manchester-Graz/Description"><img src="https://static.igem.org/mediawiki/2015/9/9a/Manchester-Graz_Description.jpg"></a>
 +
<a class="navi" href="https://2015.igem.org/Team:Manchester-Graz/Project/Vectordesign"><img src="https://static.igem.org/mediawiki/2015/1/18/Manchester-Graz_Vectordesign.jpg"></a>
 +
<a class="navi" href="https://2015.igem.org/Team:Manchester-Graz/Project/Experiments"><img src="https://static.igem.org/mediawiki/2015/3/30/Manchester-Graz_Experiments.jpg"></a>
 +
<a class="navi" href="https://2015.igem.org/Team:Manchester-Graz/Project/Results"><img src="https://static.igem.org/mediawiki/2015/5/5e/Manchester-Graz_Results.jpg"></a>
 +
<a class="navi" href="https://2015.igem.org/Team:Manchester-Graz/Attributions"><img src="https://static.igem.org/mediawiki/2015/d/dc/Manchester-Graz_Attributionssmall.jpg"></a>
 +
<a class="navi" href="https://2015.igem.org/Team:Manchester-Graz/Safety"><img src="https://static.igem.org/mediawiki/2015/d/df/Manchester-Graz_Safetysmall.jpg"></a>
 +
<a class="navi" href="https://2015.igem.org/Team:Manchester-Graz/Project/Protocols"><img src="https://static.igem.org/mediawiki/2015/8/80/Manchester-Graz_Protocols.jpg"></a>
 +
<a class="navi" href="https://2015.igem.org/Team:Manchester-Graz/Design"><img src="https://static.igem.org/mediawiki/2015/6/68/Manchester-Graz_Design.jpg"></a>
 +
 +
 +
<div id="twitterboxsmall"><a class="twitter-timeline" href="https://twitter.com/iGEMMancGraz" data-widget-id="619465263411499008" height="900" width="180">Tweets by @iGEMMancGraz</a> <script>!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs");</script>
 +
</div>
  
−
<h2>Design</h2>
+
</div>
  
−
<p>
 
−
By talking about your design work on this page, there is one medal criterion that you can attempt to meet, and one award that you can apply for. If your team is going for a gold medal by building a functional prototype, you should tell us what you did on this page. If you are going for the <a href="https://2015.igem.org/Judging/Awards#SpecialPrizes">Applied Design award</a>, you should also complete this page and tell us what you did.
 
−
</p>
 
  
−
<div class="highlightBox">
+
 
−
<h4>Note</h4>
+
<div id="inhalte" style="width:770px;">
−
<p>In order to be considered for the <a href="https://2015.igem.org/Judging/Awards#SpecialPrizes">Best Applied Design award</a> and/or the <a href="https://2015.igem.org/Judging/Awards#Medals">functional prototype gold medal criterion</a>, you must fill out this page.</p>
+
 
 +
<h1>Applied Design</h1>
 +
 
 +
 
 +
<p>iGEM Manchester-Graz’s took the first steps in the development of a novel technology for drug delivery by developing self-regulating, drug-producing bacteria. In the near future, they could be incorporated into patients’ gut micro flora to secrete medicines directly inside the body. We focused on the treatment of early stages of Parkinson’s disease, for which the current treatment involves oral administration of L-DOPA. Our talks to experts (<a href="https://2015.igem.org/Team:Manchester-Graz/Practices/Interviews" target="_blank">Interviews</a>) in the medical field showed that one of the common side effects of oral L-DOPA treatment is rapid depletion of the jejunum, were L-DOPA is mainly absorbed. In consequence L-DOPA cannot be administered orally anymore and a PEG-PEJ tube needs to be installed surgically. This way L-DOPA is injected continuously direct into the jejunum in lower concentrations (20-200mg/h) via an external pump. This so called Duodopa® therapy is not only a massive decrease of life quality but treatments costs also accumulate to over 100000$ a year per person. (<a href="https://2015.igem.org/Team:Manchester-Graz/Practices/Interviews#Högenauer" target="_blank">Interview with Dr. Högenauer</a>)</p>
 +
 
 +
<p>By working closely together with patients, experts in medicine and industry representatives we tried to design the system in the most effective way. Our regulatory system is designed to produce L-DOPA in vivo in the jejunum in probiotic bacteria such as <i>E. coli</i> Nissle 1917. Our <a href="https://2015.igem.org/Team:Manchester-Graz/Modeling" target="_blank">modeling results</a> indicate that our system is capable of producing up to 81,9 mg/h/L, what would be more than sufficient to replace the Duodopa® therapy. We focused our work on the treatment of Parkinson’s disease to give patients hope for a new perspective of life. Additionally, the system is also capable of various other applications (<a href="https://2015.igem.org/Team:Manchester-Graz/Collaborations" target="_blank">collaboration</a>). Our collaborations with UCL iGEM and Norwich iGEM showed that the system is also easy to apply on other single or multi gene pathways.</p>
 +
 
 +
<p>Furthermore, the talks to industry representatives and further investigations showed that the system can also be used as a green alternative to current chemical processes producing Dopamine or L-DOPA in the pharmaceutical industry. A greener industrial process leads to sustainable handling of natural resources and much lower waste removal or recycling costs (<a href="https://2015.igem.org/Team:Manchester-Graz/Practices/Industry" target="_blank">industry</a>).</p>
 +
 
 +
 
 +
<div style="width:900px; height:700px;"></div>
 
</div>
 
</div>
  
−
<p>This is a prize for the team that has developed a synthetic biology product to solve a real world problem in the most elegant way. The students will have considered how well the product addresses the problem versus other potential solutions, how the product integrates or disrupts other products and processes, and how its lifecycle can more broadly impact our lives and environments in positive and negative ways.</p>
+
<div id="footer">
 +
<div id="footerlinks">
 +
<div class="footerheadline">
 +
Links
 +
</div>
 +
<div class="footerlinksbox">
 +
<a class="footerlinks" href="https://2015.igem.org/Team:Manchester-Graz" style="text-decoration:none;">Home</a><br>
 +
<a class="footerlinks" href="https://2015.igem.org/Team:Manchester-Graz/Project" style="text-decoration:none";>Project</a><br>
 +
<a class="footerlinks" href="https://2015.igem.org/Team:Manchester-Graz/Team" style="text-decoration:none";>Team</a><br>
 +
<a class="footerlinks" href="https://2015.igem.org/Team:Manchester-Graz/Practices" style="text-decoration:none">Human Practices</a><br>
 +
<a class="footerlinks" href="https://2015.igem.org/Team:Manchester-Graz/Modeling" style="text-decoration:none">Modeling</a><br>
 +
<a class="footerlinks" href="https://2015.igem.org/Team:Manchester-Graz/Parts" style="text-decoration:none">Parts</a><br>
 +
</div>
 +
<div class="footerlinksbox">
 +
<a class="footerlinks" href="https://2015.igem.org/Team:Manchester-Graz/Notebook" style="text-decoration:none">Notebook</a><br>
 +
<a class="footerlinks" href="https://2015.igem.org/Team:Manchester-Graz/Attributions" style="text-decoration:none">Attributions</a><br>
 +
<a class="footerlinks" href="https://2015.igem.org/Team:Manchester-Graz/Safety" style="text-decoration:none">Safety</a><br><br><br>
 +
<a class="footerlinks" href="https://2015.igem.org" style="text-decoration:none">iGEM</a>
 +
</div>
  
−
<p>
 
−
If you are working on art and design as your main project, please join the art and design track. If you are integrating art and design into the core of your main project, please apply for the award by completing this page.
 
−
</p>
 
  
 +
</div>
 +
<div id="footercontact">
 +
<div class="footerheadline">
 +
Contact us
 +
</div>
 +
iGEM Subteam Graz<br>
 +
TU Graz, Institute of Molecular Biotechnology<br>
 +
Petersgasse 14<br>
 +
8010 Graz<br><br>
 +
 +
iGEM Subteam Manchester <br>
 +
University of Manchester<br>
 +
Manchester Institute of Biotechnology<br>
 +
131 Princess Street<br>
 +
Manchester M17DN
 +
</div>
 +
<div id="footerconnect">
 +
<div class="footerheadline">
 +
Connect
 +
</div>
 +
<a href="https://twitter.com/iGEMMancGraz" target="_blank"><img src="https://static.igem.org/mediawiki/2015/d/d0/Manchester-Graz_Twitter_64x262-03.png" alt="twitter_64x262-03" width="200" height="49"></a><br><br><br>
 +
<a href="https://www.facebook.com/pages/iGEM-Manchester-Graz/453856284768459" target="_blank"><img src="https://static.igem.org/mediawiki/2015/3/3e/Manchester-Graz_Facebook_64x262-03.png" alt="facebook_64x262-03" width="200" height="49"></a>
 +
</div>
 +
<div id="footerboringstuff">
 +
<div class="footerheadline">
 +
Boring Stuff
 +
</div>
 +
<br>
 +
<a class="footerlinks" href="https://2015.igem.org/Team:Manchester-Graz/Aboutus" style="text-decoration:none;">About us</a><br>
 +
<a class="footerlinks" href="https://2015.igem.org/Team:Manchester-Graz/Legal" style="text-decoration:none">Legal Information</a>
 +
</div>
 +
 +
<div id="footercopyright">
 +
&copy; iGEM Manchester-Graz
 +
</div>
 +
 
</div>
 
</div>
  
 +
 +
 +
 +
 +
 +
 +
 +
 +
 +
 +
 +
</div>
 +
</body>
 
</html>
 
</html>

Revision as of 20:01, 16 September 2015

iGEM Manchester Header

iGEM Manchester-Graz - Design

Applied Design

iGEM Manchester-Graz’s took the first steps in the development of a novel technology for drug delivery by developing self-regulating, drug-producing bacteria. In the near future, they could be incorporated into patients’ gut micro flora to secrete medicines directly inside the body. We focused on the treatment of early stages of Parkinson’s disease, for which the current treatment involves oral administration of L-DOPA. Our talks to experts (Interviews) in the medical field showed that one of the common side effects of oral L-DOPA treatment is rapid depletion of the jejunum, were L-DOPA is mainly absorbed. In consequence L-DOPA cannot be administered orally anymore and a PEG-PEJ tube needs to be installed surgically. This way L-DOPA is injected continuously direct into the jejunum in lower concentrations (20-200mg/h) via an external pump. This so called Duodopa® therapy is not only a massive decrease of life quality but treatments costs also accumulate to over 100000$ a year per person. (Interview with Dr. Högenauer)

By working closely together with patients, experts in medicine and industry representatives we tried to design the system in the most effective way. Our regulatory system is designed to produce L-DOPA in vivo in the jejunum in probiotic bacteria such as E. coli Nissle 1917. Our modeling results indicate that our system is capable of producing up to 81,9 mg/h/L, what would be more than sufficient to replace the Duodopa® therapy. We focused our work on the treatment of Parkinson’s disease to give patients hope for a new perspective of life. Additionally, the system is also capable of various other applications (collaboration). Our collaborations with UCL iGEM and Norwich iGEM showed that the system is also easy to apply on other single or multi gene pathways.

Furthermore, the talks to industry representatives and further investigations showed that the system can also be used as a green alternative to current chemical processes producing Dopamine or L-DOPA in the pharmaceutical industry. A greener industrial process leads to sustainable handling of natural resources and much lower waste removal or recycling costs (industry).